ArticleHypertension (Dallas, Tex. : 1979)2017
Prediction of Preeclampsia Using the Soluble fms-Like Tyrosine Kinase 1 to Placental Growth Factor Ratio: A Prospective Cohort Study of Unselected Nulliparous Women.
Article in Hypertension (Dallas, Tex. : 1979), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it, 139 citations in OpenAlex.
- Placental growth factor (PLGF)-based testing to help diagnose suspected pre-eclampsia: a systematic review and economic evaluation.Health technology assessment (Winchester, England) · 2026Pooled it
- Article
- Identification of Maternal Serum Longitudinal Signatures Through Profiling of 96 Cytokines.Life (Basel, Switzerland) · 2026Article
- Pathologic abnormalities of deep placentation in the great obstetrical syndromes: Implications for understanding the pathophysiology, risk assessment in early pregnancy, and personalized prevention.Journal of reproductive immunology · 2026Review
- First-trimester urinary glycolic acid and methylsuccinic acid measurement for preeclampsia prediction: A Systematic review protocol.PloS one · 2026Article
- Understanding Preeclampsia: Cardiovascular Pathophysiology, Histopathological Insights and Molecular Biomarkers.Medical sciences (Basel, Switzerland) · 2025Review
- Novel biomarkers for preeclampsia: Promises and pitfalls.Current opinion in obstetrics & gynecology · 2025Review
- The Placental Steroid Hypothesis of Human Brain Evolution.Evolutionary anthropology · 2025Review
- Genetic Variants Associated With Preeclampsia and Maternal Serum sFLT1 Levels.Hypertension (Dallas, Tex. : 1979) · 2025Article
- Prediction of late-onset preeclampsia using plasma proteomics: a longitudinal multi-cohort study.Scientific reports · 2024Article
- Midpregnancy Placental Growth Factor Screening and Early Preterm Birth.JAMA network open · 2024Article
- Preeclampsia at term: evidence of disease heterogeneity based on the profile of circulating cytokines and angiogenic factors.American journal of obstetrics and gynecology · 2024Article
- DEVELOPING A BEDSIDE TEST FOR PREECLAMPSIA: OVERCOMING SISYPHUS.Transactions of the American Clinical and Climatological Association · 2024Article
- Administration of Antenatal Corticosteroids: Optimal Timing.Geburtshilfe und Frauenheilkunde · 2024Article
- Sex differences in placenta-derived markers and later autistic traits in children.Translational psychiatry · 2023Article
- One-third of patients with eclampsia at term do not have an abnormal angiogenic profile.Journal of perinatal medicine · 2023Article
- Preeclampsia at term can be classified into 2 clusters with different clinical characteristics and outcomes based on angiogenic biomarkers in maternal blood.American journal of obstetrics and gynecology · 2023Article
- Association between antenatal diagnosis of late fetal growth restriction and educational outcomes in mid-childhood: A UK prospective cohort study with long-term data linkage study.PLoS medicine · 2023Article
- Increased Placental sFLT1 (Soluble fms-Like Tyrosine Kinase Receptor-1) Drives the Antiangiogenic Profile of Maternal Serum Preceding Preeclampsia but Not Fetal Growth Restriction.Hypertension (Dallas, Tex. : 1979) · 2023Article
- Histopathologic and Transcriptomic Profiling Identifies Novel Trophoblast Defects in Patients With Preeclampsia and Maternal Vascular Malperfusion.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2023Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
We sought to assess the ratio of sFlt-1 (soluble fms-like tyrosine kinase 1) to PlGF (placental growth factor) in maternal serum as a screening test for preeclampsia in unselected nulliparous women with a singleton pregnancy. We studied 4099 women recruited to the POP study (Pregnancy Outcome Prediction) (Cambridge, United Kingdom). The sFlt-1:PlGF ratio was measured using the Roche Cobas e411 platform at ≈20, ≈28, and ≈36 weeks of gestational age (wkGA). Screen positive was defined as an sFlt-1:PlGF ratio >38, but higher thresholds were also studied. At 28 wkGA, an sFlt-1:PlGF ratio >38 had a positive predictive value (PPV) of 32% for preeclampsia and preterm birth, and the PPV was similar comparing women with low and high prior risk of disease. At 36 wkGA, an sFlt-1:PlGF ratio >38 had a PPV for severe preeclampsia of 20% in high-risk women and 6.4% in low-risk women. At 36 wkGA, an sFlt-1:PlGF ratio >110 had a PPV of 30% for severe preeclampsia, and the PPV was similar comparing low- and high-risk women. Overall, at 36 wkGA, 195 (5.2%) women either had an sFlt-1:PlGF ratio of >110 or an sFlt-1:PlGF ratio >38 plus maternal risk factors: 43% of these women developed preeclampsia, about half with severe features. Among low-risk women at 36 wkGA, an sFlt-1:PlGF ratio ≤38 had a negative predictive value for severe preeclampsia of 99.2%. The sFlt-1:PlGF ratio provided clinically useful prediction of the risk of the most important manifestations of preeclampsia in a cohort of unselected nulliparous women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.